Clinical trial
Adjuvant ctDNA-Adapted Personalized Treatment in Early Stage NSCLC (ADAPT-E)
NCT04585477
Study timeline
Study start (actual)2021-04-08Date precision: day
Registry last updated2026-07-07
Observed by CureCurrent2026-10-07
Recorded dates are source observations, not predictions. Missing milestones are not estimated.
Conditions
Non-small Cell Lung Cancerunresolved
Non-small Cell Lung Cancer Stage Iunresolved
Non-small Cell Lung Cancer Stage IIunresolved
Non-small Cell Lung Cancer Stage IIIunresolved
Interventions
Sponsors & collaborators
Stanford Universitylead sponsor
AstraZenecacollaborator
Mapped research locations
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT04585477 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.